| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
116,079 |
189,843 |
233,203 |
571,547 |
| Total Sell Value |
$10,217,149 |
$17,085,208 |
$20,986,230 |
$54,848,304 |
| Total People Sold |
5 |
5 |
6 |
7 |
| Total Sell Transactions |
11 |
17 |
23 |
53 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fuchs Henry J |
EVP, Chief Medical Officer |
• – – |
2011-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
36,455 |
|
- |
|
| Cooper Jeffrey H |
SVP, Chief Financial Officer |
• – – |
2011-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
35,876 |
|
- |
|
| Davis George Eric |
SVP, General Counsel |
• – – |
2011-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
8,500 |
36,401 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2011-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
16,250 |
|
- |
|
| Lapalme Pierre |
Director |
– • – |
2011-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
21,250 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2011-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
15,250 |
|
- |
|
| Lewis Alan |
Director |
– • – |
2011-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
22,500 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2011-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
10,000 |
|
- |
|
| Young William D |
Director |
– • – |
2011-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
1,875 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2011-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
42,500 |
|
- |
|
| Mueller Brian |
VP, Corporate Controller |
• – – |
2011-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,562 |
4,175 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2011-05-10 |
4 |
S |
$25.87 |
$10,346 |
D/D |
(400) |
87,593 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2011-05-05 |
4 |
S |
$25.64 |
$5,128 |
D/D |
(200) |
87,993 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2011-05-04 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,447 |
4,149 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2011-05-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,447 |
56,439 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2011-05-04 |
4 |
S |
$25.84 |
$70,547 |
D/D |
(2,700) |
88,193 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2011-05-04 |
4 |
OE |
$9.86 |
$9,860 |
D/D |
1,000 |
90,893 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2011-05-03 |
4 |
S |
$26.68 |
$134,266 |
D/D |
(5,000) |
89,893 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2011-05-03 |
4 |
OE |
$9.86 |
$29,580 |
D/D |
3,000 |
94,893 |
|
- |
|
| Aselage Steve |
EVP, Chief Business Officer |
• – – |
2011-05-03 |
4 |
S |
$27.15 |
$279,895 |
D/D |
(10,311) |
31,478 |
|
- |
|
| Aselage Steve |
EVP, Chief Business Officer |
• – – |
2011-05-03 |
4 |
OE |
$17.33 |
$178,690 |
D/D |
10,311 |
41,789 |
|
- |
|
| Davis George Eric |
SVP, General Counsel |
• – – |
2011-05-02 |
4 |
AS |
$27.09 |
$41,452 |
D/D |
(1,530) |
27,901 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2011-04-29 |
4 |
A |
$11.64 |
$16,838 |
D/D |
1,447 |
69,160 |
|
- |
|
| Fuchs Henry J |
EVP, Chief Medical Officer |
• – – |
2011-04-29 |
4 |
A |
$13.23 |
$21,426 |
D/D |
1,620 |
24,455 |
|
- |
|
| Cooper Jeffrey H |
SVP, Chief Financial Officer |
• – – |
2011-04-29 |
4 |
A |
$11.64 |
$18,223 |
D/D |
1,566 |
28,376 |
|
- |
|
1303 Records found
|
|
Page 28 of 53 |
|
|
1.44 (1.6%) 
